Milacemide (INN)[2] is an MAO-B inhibitor and glycine prodrug.[3] It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.[4] Early clinical trials did not show positive results however,[3] and the drug is now abandoned and it is sold as a nonprescription drug or supplement. While milacemide is not an amino-acid, it acts similarly to glycine in the brain.[5]

References

  1. ↑ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
  2. ↑ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
  3. 1 2 Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type". Journal of the American Geriatrics Society. 40 (5): 503–6. doi:10.1111/j.1532-5415.1992.tb02019.x. PMID 1634705. S2CID 34816755.
  4. ↑ Harris, Carol Turkington; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X. Archived from the original on 2014-03-03. Retrieved 2017-09-10.{{cite book}}: CS1 maint: multiple names: authors list (link)
  5. ↑ Theodore I. Lidsky and Jay S. Schneider Phd, Brain Candy (2001). Brain Candy. New York, United States Of America: Simon & Schuster. ISBN 9780743218436.
source: https://en.wikipedia.org/wiki/Milacemide